Health
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia – The Lancet
The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile
and induced strong humoral and cellular immune responses in participants. Further
investigation is needed of the effectiveness of this vaccine for prevention of COVID-19.
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.
Copyright © 2020 Elsevier Inc. except certain content provided by third parties.
Privacy Policy Terms and Conditions…
-
Business23 hours agoWhy this fantastic blue chip ASX 200 share could rise 20%
-
General22 hours agoAlbanese government to freeze construction code until 2029, fast-track housing approvals
-
General15 hours agoPhotographers reveal iconic image of Gough Whitlam and Vincent Lingiari was posed on Wave Hill Walk-Off anniversary
-
Noosa News13 hours agoDog daycare program a TikTok hit for helping disabled find work, friends